Objectives: To determine whether glycine receptor ␣1 subunit-specific autoantibodies (GlyR␣1-IgG) occur in a broader spectrum of brainstem and spinal hyperexcitability disorders than the progressive encephalomyelitis with rigidity and myoclonus phenotype recognized to date, and to ascertain disease specificity.
I
NHIBITORY SYNAPTIC TRANSMISSION mediated by ␥-aminobutyric acid and glycine is critical for regulating motor neuron excitability in the brainstem and spinal cord. Central nervous system hyperexcitability disorders ascribed to loss of this input are characterized by exaggerated startle, stiffness, and spasms of the axis and limbs. Autoimmunity accounts for classic stiff-man syndrome (SMS; also known as stiff-person syndrome), which principally affects the lumbar spine and proximal lower extremities), 1,2 variant SMS (limited to the axis or extremities [eg, stiff-leg syndrome]), 3 and progressive encephalomyelitis with rigidity and myoclonus (PERM), 4 in which hyperexcitability is widespread, severe, and sometimes fatal. Autoantibodies specific for the 65 kDa isoform of the ␥-aminobutyric acid-synthesizing enzyme glutamic acid decarboxylase 65 (GAD65)-IgG are detected in 80% of patients with classic SMS. 5 Other autoantigens pertinent to SMS phenotype include amphiphysin, 6 gephyrin, 7 and the ␣1 subunit of a heteromeric (␣1␤) glycine-gated chloride channel (GlyR␣1) 8 that is enriched in the spinal cord and brainstem. 9 Published reports have emphasized an association of GlyR␣1-IgG with the rare PERM phenotype. 8, [10] [11] [12] [13] [14] However, to our knowledge, this autoantibody has not been investigated systematically in more common forms of brainstem and spinal cord hyperexcitability, including classic and variant SMS.
METHODS
This study was approved by the institutional review boards of Mayo Clinic (Rochester, Minnesota) and the Hospital Clinic (University of Barcelona, Spain).
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DETECTION OF GlyR␣1 AUTOANTIBODIES (UNIVERSITY OF BARCELONA)
HEK293 cells were transfected, as reported previously, 15 with a plasmid (pRK5) containing the human GlyR␣1 subunit cDNA, or control plasmid without insert. After culturing for 24 hours posttransfection, the cells were fixed and permeabilized for 10 minutes (4% paraformaldehyde and 0.3% Triton X-100), washed in phosphate-buffered saline, and held overnight at 4ЊC with patient serum (1:40) or cerebrospinal fluid (CSF; 1:5) plus a monoclonal mouse IgG specific for a noncompeting epitope of GlyR␣1 (residues 96-105; Synaptic Systems SYSY; diluted 1:500). Bound human and mouse IgGs were demonstrated after holding 1 additional hour at 37ЊC with Alexa Fluor-conjugated IgGs specific for human IgG (488) and mouse IgG (594), respectively, both diluted 1:1000 (molecular probes; Invitrogen). Resulting images were visualized by fluorescence microscope and captured using Zeiss Axiovision software (Zeiss).
PATIENTS
Medical records were reviewed at Mayo Clinic. Coded specimens of serum and CSF were tested for GlyR␣1-IgG. Interpreting serologists at the University of Barcelona were blinded to clinical diagnosis. Patients from the following groups were tested.
SMS PHENOTYPE
Serum samples collected during 25 years (Mayo Clinic, 1984-2011; Figure 1) were from 81 patients of a previously described cohort with classic SMS and phenotypically similar disorders 5 for whom at least 1 sample was available from the time of diagnosis (80 serum samples and 14 CSF specimens). Mayo Clinic's computerized diagnostic index was searched for patient diagnoses where neurologic hyperexcitability was the predominant phenotype: stiff-man syndrome; stifflimb syndrome; stiff-person syndrome; and progressive encephalomyelitis, rigidity, myoclonus, and hyperekplexia. The diagnosis of SMS or PERM was made by the treating physician. Patients were diagnosed as having PERM if they had a rapidly progressive encephalomyelopathy accompanied by wholebody stiffness, spasms, and myoclonus. We retrospectively classified SMS as classic or variant. Patients were classified as having classic SMS if lower extremity and lumbar stiffness and spasms were present, and variant SMS if symptoms were restricted to either axial or extremity muscles or upper body muscles. Patients with hyperekplexia had isolated exaggerated startle in response to tactile or auditory stimuli.
Clinical, serologic, CSF, neurophysiological, radiologic, treatment, and outcome data were recorded from the medical records of all patients. Electrophysiological studies consisted of multichannel surface electromyography recording over the right orbicularis oculi, sternocleidomastoid, biceps, abductor pollicis brevis, thoracic paraspinals, lumbar paraspinals, anterior tibialis, gastrocnemius, and soleus muscles. Auditory startle reflexes (pattern and habituation of motor responses) were evaluated using binaural 105 dB intensity stimuli 1 minute apart during 3 to 5 trials. 16 Exteroceptive responses were determined by electrically stimulating the medial plantar nerve. 17 Concentric needle studies were performed in some patients on the lumbar paraspinal or limb muscles.
CONTROL GROUPS
A total of 100 patients (81 serum samples and 46 CSF specimens) represented 5 groups: (1) other autoimmune neurologic disorders (n=13 [4 with encephalopathy, 3 with seizure disorder, 2 with neuropathy, 1 with cerebellar ataxia, 1 with brainstem disorder, 1 with myelopathy, and 1 with neuromyelitis optica]; 6 were GAD65-IgG positive); (2) idiopathic demyelinating diseases (n=12 [10 with multiple sclerosis and 2 with monophasic optic neuritis]); (3) miscellaneous neurologic disorders (n=15 [2 with myelopathy; 2 with fibromyalgia; and 1 each with indeterminate spells, dementia, ataxia, seizure disorder, optic atrophy, central nervous system sarcoidosis, neuropathy, hereditary hyperekplexia, progressive multifocal leukoencephalopathy, Huntington disease, and viral meningoencephalitis]); (4) paraneoplastic or idiopathic autoimmune encephalitis (n=40) and the following antibodies: N-methyl-D-aspartate receptor antibody (n=10), ␥-aminobutyric acid B receptor antibody (n=5), leucinerich, glioma-inactivated 1 (n=10), and ANNA types 1 (anti-Hu; n=10) and 2 (anti-Ri); and (5) serum samples from 20 healthy subjects also were tested.
STATISTICAL ANALYSIS
We compared GlyR␣1-IgG-positive and GlyR␣1-IgGnegative patients with SMS phenotype with respect to age at onset, distribution of stiffness and spasms, and coexisting neurologic disorders using Fisher exact test or Wilcoxon rank sum test where appropriate ( JMP version 8.0; SAS Institute).
RESULTS
Ten of the 81 patients with SMS phenotype (12%) were GlyR␣1-IgG positive: 5 had variant SMS, 4 had classic SMS, and 1 had PERM ( Figure 1 and Figure 2 ). Glycine receptor ␣1-IgG was detected in 6 of 80 available serum samples (7.5%) and in 6 of 14 available CSF specimens (43%). Glycine receptor ␣1-IgG was detected in 6 of 60 serum samples that were GAD65-IgG positive (10%) and in 4 of 21 serum samples that were GAD65-IgG negative (19%). Glycine receptor ␣1-IgG was not detected in any amphiphysin-IgG-positive serum. The frequency of GlyR␣1-IgG was not significantly greater among patients with classic SMS (4/45), variant SMS, or PERM (6/35; P=.32). One (patient 11) of the 80 neurologic control patients' serum samples (1.2%) was positive for GlyR␣1-IgG; CSF was negative. None of the 20 healthy subjects' serum samples was GlyR␣1-IgG positive. , and hyperekplexia) were tested for glycine receptor ␣1 (GlyR␣1)-IgG.
GlyR␣1-IgG-POSITIVE PATIENTS
The 11 patients in whom GlyR␣1-IgG was detected (10 cases, 1 control subject) are described in Table 1 and Table 2 (6 were women). The median age at symptom onset was 43 years (range, 5-69 years). Ethnicities were white (n = 9); African American (n = 1), and unknown (n=1). Among patients with SMS phenotype, age at symptom onset was not significantly different in seropositive and seronegative patients (Wilcoxon rank sum test; P = .35). Median follow-up from diagnosis was 12 months (range, 0-60 months). Response rates to treatment with benzodiazepines were similar for seropositive patients (6 of 7 improved) and seronegative patients (62 of 68 improved). Among patients for whom we had immunotherapy data (treatments were heterogenous), substantial improvements were noted in 5 of 6 seropositive patients compared with 7 of 25 seronegative patients (P = .02).
ILLUSTRATIVE PATIENTS Patient 1
At age 29 years, this man developed jerking of his right foot that subsequently spread to his lower back. On examination, he had stiffness and superimposed spasms of the lumbar paraspinal muscles and lower extremities. Despite being seronegative for GAD65 Ab, he was diagnosed as having classic SMS because the clinical findings were characteristic. He improved considerably with diazepam therapy. At age 41 years, he was diagnosed as having stage IV Hodgkin lymphoma. Within 1 month of starting adriamycin, bleomycin, vinblastine, and dacarbazine therapy, stiffness worsened and spasms progressed to affect the whole body; he also developed severe startle, fear of falling, and anxiety. Electrophysiological studies were consistent with SMS. Symptoms improved periodically during the ensuing 12 months of treat- ment with methylprednisolone, prednisone, and intravenous immune globulin. One year later, lymphoma was in remission and the neurologic symptoms had improved considerably.
Patient 3
A 55-year-old woman with autoimmune thyroid disease reported that scoliosis and toe walking were noted at age 5 years. From teen years onwards, she experienced gaitfreezing spells. While in her 20s, she noted anxiety and easy startling. Stiffness and spasms in the low back and lower extremities began when she was in her 50s. Examination revealed exaggerated lumbar lordosis, stiffness, and spasms of the lumbar region and lower extremities. She was diagnosed as having classic SMS. She was GAD65-IgG positive. After treatment for 1 year with azathioprine and prednisone, examination revealed mildly exaggerated lumbar lordosis.
Patient 6
A 17-year-old boy reported that pain and spasms restricted to the thoracic and lumbar regions began at age 14 years. Examination revealed slight scoliosis and involuntary spasms of the thoracic paraspinal muscles. Electromyograph demonstrated continuous motor unit activity in those muscles. He was diagnosed as having variant SMS, with restricted involvement of the back muscles. He was GAD65-IgG low positive. Mild improvement was observed with diazepam therapy. Immunotherapy conferred significant improvement but relapse was rapid after discontinuing plasma exchange.
Patient 11
A 42-year-old man experienced bilateral blurring of vision, which worsened progressively during 1 year then stabilized. He experienced no stiffness, spasms, or other motor symptoms. Eye examination 2 years after symptom onset revealed bilateral optic atrophy without observable retinal abnormalities; visual acuity was 20/400 bilaterally. Head magnetic resonance imaging demonstrated nonenhancing T2-signal abnormalities in the superior colliculi, superior cerebellar peduncles, left brachium pontis, and bilateral occipital white matter. After a 6-week trial of corticosteroid therapy, the patient reported improved vision; visual acuity was 20/200 (right eye) and 20/150 (left eye).
COMMENT
The current study revealed that 12% of patients with an acquired SMS phenotype, with and without GAD65-IgG, were seropositive for GlyR␣1-IgG. A neoplasm (Hodgkin lymphoma) was identified in 1 of 10 GlyR␣1-IgG-positive patients. Cancers reported to date in GlyR␣1-IgG-positive patients include thymoma 13 and lung cancer. 19 Similar to a previously reported seropositive patient who had thymoma, 13 our patient with Hodgkin lymphoma improved neurologically after cancer treatment. The frequency of cancer accompanying GlyR␣1-IgG remains to be determined.
The greater frequency of substantial clinical improvement in GlyR␣1-IgG-seropositive SMS phenotype patients suggests that GlyR␣1-IgG may predict immunotherapy responsiveness. However, the heterogeneity of immunotherapy regimens used and the retrospective ascertainment of responses from medical record review preclude definitive conclusions. Prospective studies could clarify this question. Although the pathogenicity of GlyR␣1-IgG is yet unproven, immunotherapy responsiveness has been documented for other neurologic disorders characterized serologically by IgGs targeting neuronal cell surface proteins. 15 In contrast, GAD65-IgG recognizes a cytoplasmic-facing synaptic vesicle protein. 2 The IgGs that are specific for cytoplasmic and nuclear autoantigens are considered surrogate markers of inflammatory organspecific autoimmune disorders mediated by cytotoxic T cells, a hypothesis supported by autopsy findings in some patients with SMS. 20 Immunotherapy responses in GAD65-IgG-positive patients with SMS phenotype are variable and posttherapy normalization is uncommon. 5, 21 As recognized in early reports, 8, [10] [11] [12] [13] [14] GlyR␣1-IgG was highly specific for brainstem/spinal cord hyperexcitability disorders. However, our detection among 80 disease specificity (neurologic) control samples of a single seropositive patient with immunotherapy-responsive progressive vision loss and inflammatory CSF, in the absence of SMS phenotype, suggests that the spectrum of GlyR␣1 receptor autoimmunity extends beyond the spinal cord and brainstem. Of pertinence, glycine and ␥-aminobutyric acid are the major inhibitory neurotransmitters of human retina. 22 Consistent with the clinical disorders we encountered with GlyR␣1-IgG, in situ hybridization studies have revealed that GlyR␣1 messenger RNA is largely restricted to the retina, brainstem, and spinal cord. 22 Systematic investigation of the neuroophthalmologic spectrum of glycine receptor autoimmunity is needed.
